Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00337-1/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=276355044&_hsenc=p2ANqtz-9vvVSJPZ0uRzJOCIkizPLLO9BLi3kZQEQReGTLsKkPkE6CpE5dWLdainCWxY9cXJQovOemNs1aOgGOCvEi4WpjJrN7MA&utm_content=276317812&utm_source=hs_email